REACHING THE THERAPEUTIC GOAL IN HYPERTENSION: RESULTS FROM THE CANADIAN VALSARTAN OBSERVATIONAL STUDY (DIOVANTAGE 4)
Main Article Content
Keywords
Blood pressure, compliance, hypertension, valsartan, health care delivery, behavior modification
Abstract
Background
Hypertension is a leading cause of death worldwide, and a major public health problem in Canada. Despite treatment guidelines and availability of therapies for blood pressure (BP) management, treatment of hypertension remains sub-optimal.
Objectives
The objectives of this trial are to observe BP reduction, compliance and regimen changes 3 months after initiation of valsartan alone or with hydrochlorothiazide and optimized patient support.
Methods
As of February 2007, 34,033 patients with essential hypertension and prescribed valsartan alone or with hydrochlorothiazide for BP management were enrolled across 2,125 Canadian sites. Patients were newly diagnosed (38%), switched from another anti-hypertensive agent (38%) or received valsartan with or without hydrochlorothiazide as added therapy (20%). All patients were offered a home blood pressure monitor, access to nursing support and educational materials. Patients were assessed after 3 months for compliance, therapeutic response, and need for treatment modifications.
Results
In this interim analysis, after 3 months of treatment, 95% of patients reported being compliant with therapy and 59% achieved target BP (<140/90 mmHg). In the evaluable population (n=15,200), significant reductions in mean systolic (-18.5±19.3 mm/Hg, p<0.0001) and diastolic (-9.4±11.2 mmHg; p<0.0001) BP were observed. For patients not reaching target BP goals, no change in treatment was instituted in 55% of cases.
Conclusions
This observational study demonstrates the benefits of valsartan alone or with hydrochlorothiazide and optimized patient support in BP management of patients with essential hypertension. Interestingly, no modification to the anti-hypertensive regimen was done in 55% of patients not having reached treatment goals.
References
2. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244-1263.
3. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens. 1997;10:1097-1102.
4. Five-year Findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562-2571.
5. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
7. MacLean DR, Petrasovits A, Nargundkar M, et al. Canadian heart health surveys: a profile of cardiovascular risk. Survey methods and data analysis. Canadian Heart Health Surveys Research Group. Can Med Assoc J. 1992;146:1969-1974.
8. Joffres MR, Hamet P, MacLean DR, L'italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens. 2001;14:1099-1105.
9. Feldman RD, Campbell N, Larochelle P, et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. Can Med Assoc J. 1999;161(Suppl 12):S1-S17.
10. Campbell NR, Tu K, Brant R, Duong-Hua M, McAlister FA. Canadian Hypertension Education Program Outcomes Research Task Force. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension. 2006;47:2228.
11. Touyz RM, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R. Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension. Can J Cardiol. 2004;20:55-59.
12. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II – therapy. Can J Cardiol. 2005;21:657-672.
13. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289: 2560-2572.
14. Petrella RJ, Campbell NR. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol. 2005;21:589-593.
15. Muirhead N, Feagan BF, Mahon J. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res. 1999;60:650-660.
16. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/hydrochlorothiazide is effective in hypertensive patient inadequately controlled by valsartan monotherapy. Blood Press. 2003;1 (Suppl):36-43.
17. Mallion JM, Boutelant S, Chabaux P. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an Angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 1997; 2:179-184.
18. Heart and Stroke Foundation of Canada: The Growing Burden of Heart Disease and Stroke in Canada 2003. Ottawa, Canada.
19. Economic Burden of Illness in Canada, 1998 Policy Research Division, Strategic Policy Directorate, Population and Public Health Branch, Health Canada.
20. Gill JS, Zezulka AV, Beevers DG, Davies P. Relation between initial blood pressure and its fall with treatment. Lancet. 1985;1:567-569.
21. Ferrari P, Hess L, Pechere-Bertschi A, et al. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens. 2004;22:1221-1229.
22. Kannel WB. An overview of risk cardiovascular disease. In: Kaplan, Neward, Stanler, eds. Prevention of Coronary Disease, Practical Management of Risk Factors. Philadelphia: WB Saunders, 1983.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703– 713.
24. Tobe S, McAlister FA, Leiter L. Applying the 2005 Canadian Hypertension Education Program recommendations: 5. Therapy for patients with hypertension and diabetes mellitus Can Med Assoc J. 2005;173:1154-1157.
25. Abts M, Claus V, Lataster M. Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: The MACHT Observational Study. Blood Press. 2006;15(Suppl 1):27-32.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.